Medical Oncologist
HER2-positive breast cancer
Trastuzumab emtansine (T-DM1) after residual disease
Trastuzumab emtansine, or T-DM1, is trastuzumab joined to a chemotherapy drug. For women with HER2-positive breast cancer that remains at surgery after treatment beforehand, switching to T-DM1 afterwards lowers the chance of recurrence. This page explains, in general terms, how it works and what a course involves.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- Why is T-DM1 used when cancer remains after treatment?
- Trastuzumab and T-DM1 after surgery
- The effects most worth knowing about
- What a course of T-DM1 usually involves
- The vocabulary, in plain language
- What to expect honestly
- Other treatments that may run at the same time
- Coping when surgery shows cancer remained
- Planning around infusion days
- What people assume about T-DM1
- Common questions about T-DM1
The short answer
Why is T-DM1 used when cancer remains after treatment?
Trastuzumab emtansine, often called T-DM1, is trastuzumab joined to a chemotherapy drug. The antibody carries the chemotherapy directly to cancer cells that carry the HER2 protein. For women with early HER2-positive breast cancer who still have invasive cancer at surgery after treatment beforehand, switching from trastuzumab to T-DM1 after surgery has been shown to lower the chance of the cancer returning.
Why the switch makes sense
Cancer remaining at surgery suggests it was less sensitive to the first treatment. T-DM1 delivers a different kind of attack, bringing chemotherapy right to the cancer cells, which helps in this higher-risk situation.
What the course involves
An infusion every three weeks, usually to complete the planned year of HER2-targeted treatment after surgery. Radiation and hormone therapy can often continue alongside it where they are needed.
Who it may not suit
Women whose cancer cleared completely at surgery usually continue with trastuzumab, with or without pertuzumab, instead. People with significant liver problems, heart problems or very low platelet counts may also need a different plan.
This page gives general information only. Whether T-DM1 is right for you is a decision for your oncologist.Side by side
Trastuzumab and T-DM1 after surgery
Continuing trastuzumab
Switching to T-DM1
Usual when cancer cleared at surgery
Usual when invasive cancer remained
Antibody alone
Antibody carrying a chemotherapy drug
Few side effects on its own
Tiredness, low platelets and liver changes more common
Heart scans needed
Heart scans and closer blood tests needed
Lower drug cost
Higher drug cost
Side effects
The effects most worth knowing about
Hair loss is uncommon with T-DM1. These are the effects your team watches for most closely.
Tiredness
The most common side effect. It often comes in waves after each infusion. Gentle activity and rest help many people cope.
A low platelet count
Platelets help blood clot. A drop can cause easy bruising, nosebleeds or bleeding gums. Blood tests before each dose check the count.
Report unusual bleeding promptly.Liver changes
Liver blood tests can rise. They are checked before every dose, and the dose may be lowered or paused if they rise too far.
Numbness and tingling
Nerve effects in the hands and feet can build up, especially after earlier taxane treatment. Mention any change at your reviews.
Call your team if
- You bleed or bruise easily
- Your skin or eyes turn yellow
- You become breathless or swollen
How it is given
What a course of T-DM1 usually involves
Blood tests before every dose
Platelets and liver tests are checked before each infusion to make sure it is safe to go ahead.
A longer first infusion
The first dose runs slowly with observation afterwards. Later infusions are shorter if the first goes well.
Every three weeks
Infusions repeat every three weeks, usually to complete the planned course after surgery.
Heart scans
Heart function is checked every few months, as with other HER2 treatments.
Adjusting when needed
If side effects build up, the dose may be lowered or treatment paused. Sometimes the plan is switched back to trastuzumab.
Words you will hear
The vocabulary, in plain language
- T-DM1
- A short name for trastuzumab emtansine.
- Antibody-drug conjugate
- An antibody joined to a chemotherapy drug, so the drug is carried to cancer cells.
- Residual disease
- Invasive cancer still present at surgery after treatment beforehand.
- Platelets
- Blood cells that help clotting. T-DM1 can lower them.
- Liver function tests
- Blood tests that show how the liver is coping with treatment.
- Pathological complete response
- No invasive cancer left at surgery. When this happens, T-DM1 is not usually needed.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
What to expect honestly
Hearing that cancer remained after treatment before surgery is disappointing. It does not mean treatment failed. It means the next step needs to be a little different, and T-DM1 exists precisely for this situation.
The benefit is real
In a large study, women who switched to T-DM1 after residual disease had a clearly lower chance of the cancer returning than those who continued trastuzumab. It lowers that chance, though it cannot remove it entirely.
Side effects differ from trastuzumab
Because T-DM1 carries chemotherapy, it brings more side effects than trastuzumab on its own, especially tiredness and changes in blood tests. Most are manageable with dose changes.
Cost matters
T-DM1 is expensive. Ask your team early about costs and any support options that may be available.
What this page cannot tell you
It cannot tell you your own risk or benefit. Ask your oncologist what your surgery results mean and why T-DM1 is recommended.
Alongside T-DM1
Other treatments that may run at the same time
T-DM1 is usually one part of the plan after surgery rather than the only treatment.
Radiation therapy
If radiation is planned after surgery, it can often be given while T-DM1 continues. Your team coordinates the timing.
Hormone therapy
If your cancer is also hormone-sensitive, hormone tablets or injections are usually started alongside T-DM1 and continue for several years after it ends.
Follow-up care
Regular reviews, blood tests and heart scans continue through the course, and follow-up appointments continue once it finishes.
Hearing the result
Coping when surgery shows cancer remained
Many women go into surgery hoping the treatment beforehand has cleared the cancer completely. Learning that some remained can feel like a setback, even when the surgeon has removed everything that was left.
What the result really tells you
The pathology report shows how the cancer responded, which helps your oncologist choose the most useful treatment after surgery. It is information that improves your plan, not a verdict on how things will turn out.
Talking it through
Ask your oncologist to explain how much cancer remained, whether lymph nodes were involved, and what that means for your outlook with T-DM1. Bringing a family member to that conversation helps many women take in the details.
Getting support
Disappointment, fear and tiredness after a long stretch of treatment are common. Counsellors, support groups and other women who have been through the same step can make the next months feel less lonely.
Practical matters
Planning around infusion days
The course runs for many months, so a steady routine helps.
Before each visit
Have your blood test at the time your team suggests, eat a light meal, and bring a list of any bruising, bleeding or new symptoms since your last dose.
Between visits
Pace yourself around the tired days, avoid contact sports while platelets are low, and use a soft toothbrush to protect your gums.
Commonly believed
What people assume about T-DM1
Cancer left after chemotherapy means nothing more can help.
T-DM1 was developed for exactly this situation and has been shown to lower the chance of recurrence. Residual disease changes the plan; it does not end it.
T-DM1 is just trastuzumab under another name.
It is trastuzumab joined to a chemotherapy drug. That makes it work differently, and it has different side effects.
I will lose my hair again.
Hair loss is uncommon with T-DM1. Hair that fell out during earlier chemotherapy usually continues to regrow.
Low platelets mean I must stop for good.
A drop in platelets is common and is usually managed by pausing or lowering the dose. Your team decides based on your blood tests.
Questions we are asked
Common questions about T-DM1
How many doses of T-DM1 will I have?
Usually enough to complete the planned course of HER2-targeted treatment after surgery, given every three weeks. Your oncologist will tell you the exact number and may adjust it if side effects build up.
Is T-DM1 used in metastatic breast cancer?
Yes. It is also used in metastatic HER2-positive breast cancer, usually after earlier HER2 treatments. The goals and schedule there differ from early breast cancer.
What should I do about bruising or nosebleeds?
Tell your team, especially if bleeding is prolonged or you notice many bruises. Avoid medicines that thin the blood unless your team has approved them.
Can I have radiation at the same time?
Often yes. Radiation after surgery can usually be given while T-DM1 continues. Your team will plan the timing.
Why are my liver tests checked so often?
T-DM1 can raise liver enzymes. Checking before each dose lets your team adjust treatment early if needed.
Is it safe during pregnancy?
No. Effective contraception is needed during treatment and for some time afterwards. Ask your team how long.
What if I cannot tolerate it?
The dose can be lowered, treatment paused, or the plan switched back to trastuzumab. Your oncologist will discuss the options with you.
Where can I read about this drug?
Your oncology team will give you written information about T-DM1, including side effects and what to report. Use that as your main reference.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Cancer Research UK — Trastuzumab emtansine (Kadcyla)
- National Cancer Institute — Ado-trastuzumab emtansine
- New England Journal of Medicine — Trastuzumab emtansine for residual invasive HER2-positive breast cancer (KATHERINE)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.